Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
Atavistik Bio, Inc
Alterome Therapeutics, Inc.
Eli Lilly and Company
BeOne Medicines
ViroMissile, Inc.
Tizona Therapeutics, Inc
Leiden University Medical Center
Clasp Therapeutics, Inc.
Eli Lilly and Company
Angiex, Inc.
IDEAYA Biosciences
Eli Lilly and Company
Oscotec Inc.
Innate Pharma
MOMA Therapeutics
NeoTX Therapeutics Ltd.
National Cancer Institute (NCI)
Exelixis
Senhwa Biosciences, Inc.
Jonsson Comprehensive Cancer Center
Novita Pharmaceuticals, Inc.
Eli Lilly and Company
NextPoint Therapeutics, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Columbia University
Theratechnologies
Tomsk National Research Medical Center of the Russian Academy of Sciences
Carisma Therapeutics Inc
Zumutor Biologics Inc.
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Optimal Health Research
Danatlas Pharmaceuticals Co., Ltd
Pfizer
Pfizer
NGM Biopharmaceuticals, Inc
Haihe Biopharma Co., Ltd.
OHSU Knight Cancer Institute
Pfizer
Prelude Therapeutics
Leap Therapeutics, Inc.
Tomsk National Research Medical Center of the Russian Academy of Sciences
Hoffmann-La Roche
Lebanese University
Canadian Cancer Trials Group
Nuvation Bio Inc.